Related Experiment Video
Updated: Jul 25, 2025
06:03
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
619
Pulmonary fibrosis and type-17 immunity.
Satoru Senoo1, Hisao Higo2, Akihiko Taniguchi1
1Department of Hematology, Oncology, Allergy and Respiratory Medicine, Okayama University Academic Field of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Respiratory Investigation
|June 25, 2023
Summary
Type-17 immunity, driven by cytokines like IL-23, promotes pulmonary fibrosis by activating pathways that induce tissue remodeling and inhibit protective autophagy. Targeting this immune response offers a potential therapeutic strategy for lung fibrosis.
Area of Science:
- Immunology
- Pulmonary Medicine
- Cell Biology
Background:
- Pulmonary fibrosis, a severe lung disease, involves complex cellular and molecular mechanisms.
- Key growth factors like transforming growth factor-beta (TGF-β) and cytokines, including interleukins (ILs), are implicated in fibrosis development.
- Type-17 immunity, a specific immune response, has emerged as a significant contributor to pulmonary fibrosis pathogenesis.
Purpose of the Study:
- To elucidate the role of type-17 immunity in the pathophysiology of pulmonary fibrosis.
- To investigate the mechanisms by which type-17 immunity contributes to lung fibrosis.
- To explore the potential of targeting type-17 immunity as a therapeutic strategy for pulmonary fibrosis.
Main Methods:
- Review of existing literature on pulmonary fibrosis and type-17 immunity.
- Analysis of the molecular pathways involving cytokines (e.g., IL-17A, IL-23) and their cellular targets.
- Examination of the components of type-17 immunity, including various immune cells and their functions.
Main Results:
- Type-17 immunity, characterized by cells like T helper 17 cells and IL-17A-producing CD8+ T cells, is activated by cytokines such as IL-1β, IL-6, and IL-23.
- The key cytokine IL-17A promotes epithelial-mesenchymal transition, stimulates fibroblasts and fibrocytes, and inhibits autophagy, a process protective against fibrosis.
- IL-23 plays a crucial role in inducing type-17 immunity and exacerbating pulmonary fibrosis, with clinical evidence supporting its link to the disease.
Conclusions:
- Type-17 immunity is a critical driver of pulmonary fibrosis.
- Targeting IL-17A, IL-23, or other components of type-17 immunity presents a promising therapeutic avenue.
- Intervention strategies aimed at modulating type-17 immunity could prevent or mitigate the progression and exacerbation of pulmonary fibrosis.
More Related Videos
Related Concept Videos
01:24T Cell Types and Functions
1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.9K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.9K
01:30Pulmonary Hypertension: Classification and Pathogenesis
234
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
234
01:17Other Pulmonary Disorders
875
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
875
01:29Pulmonary Tuberculosis I
286
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
286
01:28Pulmonary Tuberculosis II
281
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
281